Inclusion Criteria:
Group 1 Patients with Parkinson's disease and impulse control disorders
- Patients with a diagnosis of clinically established or clinically probable Parkinson's disease according to the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease
- Patients aged ≥ 30 and ≤ 80 years old
- Patients presenting currently with impulse control disorders or having presented with impulse control disorders in the last 2 years (Ardouin Behavior Scale score ≥2 for one or more of the following items: eating behavior; compulsive buying; pathological gambling; hypersexuality) , following the diagnosis of Parkinson's disease
- Patients able to sign the consent document and willing to participate in all aspects of the study
Patients with Parkinson's disease and without impulse control disorders
- Patients with a diagnosis of clinically established or clinically probable Parkinson's disease according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease
- Patients aged ≥ 30 and ≤ 80 years old
- Patients not currently presenting with impulse control disorders and other hyperdopaminergic behaviors and not having ever presented with impulse control disorders
- Patients able to sign a consent document and willing to participate in all aspects of the study
Group 2 : Healthy volunteers
Subjects aged ≥ 30 and ≤ 80 years old
- Subjects not currently presenting with impulse control disorders or hyperdopaminergic behaviors and not having ever presented with impulse control disorders
- Subjects able to sign a consent document and willing to participate in all aspects of the study
Exclusion Criteria:
Group 1 :
Patients with Parkinson's disease and impulse control disorders
- Patients with Montreal Cognitive Assessment score ≤24 or Frontal Assessment Battery score ≤14
- Patients not able to perform Positron Emission Tomography (PET) or Magnetic Resonance Imaging (MRI)
- Patients presenting with other severe medical condition or other parkinsonian syndrome
- Patients treated with Deep Brain Stimulation or levodopa pump
- Patients treated with drugs or consuming recreative drugs specifically interfering with the serotoninergic, noradrenergic or opiate systems in the last 3 months
- Patients presenting with substance dependence, except for tobacco
- Patients with Body Mass Index ≥ 35kilogram/meters2 (kg/m2)
Patients with Parkinson's disease and without impulse control disorders
- Patients with Montreal Cognitive Assessment score ≤24 or Frontal Assessment Battery score ≤14
- Patients not able to perform Positron Emission Tomography or Magnetic Resonance Imaging
- Patients presenting with other severe medical condition or other parkinsonian syndrome
- Patients treated with Deep Brain Stimulationor levodopa pump
- Patients treated with drugs or consuming recreative drugs specifically interfering with the serotoninergic, noradrenergic or opiate systems in the last 3 months
- Patients presenting with substance dependence, except for tobacco
- Patients with Body Mass Index ≥35kg/m2
Group 2 : Healthy volunteers
- Subjects with Montreal Cognitive Assessment score ≤24 or Frontal Assessment Battery score ≤14
- Subjects not able to perform Positron Emission Tomography or Magnetic Resonance Imaging
- Subjects presenting with neurologic, psychiatric or other severe medical condition
- Subjects treated with drugs or consuming recreative drugs specifically interfering with the serotoninergic, noradrenergic or opiate systems in the last 3 months
- Subjects presenting with substance dependence, except for tobacco
- Subjects with Body Mass Index ≥35kg/m2